Ezetimibe vs Oxandrolone
FDA Approved vs Well Studied
compatible Researched · 90% A common pairing in the steroid community. Oxandrolone (Anavar) is notorious for severely suppressing HDL (often by 50% or more) and raising LDL. Ezetimibe helps mitigate the LDL component of this dyslipidemia without adding hepatic stress to an already liver-burdened cycle. While ezetimibe does not directly improve HDL, controlling LDL helps manage overall cardiovascular risk during Anavar cycles.
Molecular Data
Ezetimibe Oxandrolone
Weight 409.43 Da 306.44 Da
Half-life ~22 hours ~9-10 hours
Type Azetidinone (C24H21F2NO3) 17-alpha-alkylated anabolic-androgenic steroid (C19H30O3)
Key Benefits
Ezetimibe
01 Reduces LDL cholesterol by 15-20% as monotherapy
02 Complementary mechanism to statins allows additive LDL reduction of 25% when combined
03 Minimal hepatotoxicity, making it suitable alongside hepatotoxic oral AAS
04 Simple once-daily dosing with no titration required
05 No significant impact on CoQ10 levels (unlike statins)
06 Well tolerated with a side effect profile comparable to placebo in clinical trials
07 Proven cardiovascular outcome benefit when added to statin therapy (IMPROVE-IT trial)
08 Helps manage the severe lipid disruption caused by oral steroids like Anavar and Winstrol
Oxandrolone
01 Promotes lean muscle mass gains with minimal water retention
02 Supports recovery of lost body weight following surgery, trauma, or chronic illness
03 Reduces bone pain associated with osteoporosis and improves bone mineral density
04 Does not aromatize to estrogen, avoiding estrogen-related side effects
05 Well-studied safety profile in women, children, and burn patients
06 Enhances nitrogen retention and protein synthesis during caloric deficit
07 Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
08 Lower androgenic potency compared to most oral anabolic steroids
Side Effects
Ezetimibe
Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo
Upper respiratory tract infection (reported in clinical trials but not clearly drug-related)
Fatigue and headache (uncommon, typically transient)
Oxandrolone
HDL cholesterol suppression (dose-dependent, most significant lipid effect)
LDL cholesterol elevation
Mild hepatic stress (elevated liver enzymes ALT/AST)
Suppression of endogenous testosterone production
Mild headaches
Nausea or gastrointestinal discomfort
Changes in libido (increase or decrease depending on hormonal context)
Oily skin and mild acne
Contraindications
Known hypersensitivity to ezetimibe or any component of the formulation
Active liver disease or unexplained persistent elevations in hepatic transaminases (when combined with a statin)
Pregnancy and breastfeeding (when used in combination with a statin)
Known or suspected prostate cancer
Breast cancer in males
Breast cancer with hypercalcemia in females
Pregnancy (Category X - known to cause fetal harm)
Nephrosis or nephrotic phase of nephritis
Hypercalcemia
Severe hepatic dysfunction or active liver disease
Hypersensitivity to oxandrolone or any formulation component
Research Evidence
Ezetimibe Oxandrolone
Status FDA Approved Well Studied
References 5 studies 5 studies
Latest 2023 September 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.